Actively Recruiting
Study of Tegavivint and Gemcitabine Combination Treatment in Patients Aged 1 to 30 Years with Relapsed or Refractory Osteosarcoma
Led by Emory University · Updated on 2026-10-19
24
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the combination of Tegavivint and Gemcitabine in patients aged 1 to 30 years with relapsed or refractory osteosarcoma, a type of bone cancer that has returned or not responded to previous treatment. This Phase 1 trial aims to find the maximum tolerated dose and recommended dose for future studies, while also examining the side effects of this drug combination. Osteosarcoma has a poor prognosis after relapse, and there are currently no chemotherapy treatments proven to improve survival significantly in these patients. Participants receive Tegavivint and Gemcitabine in cycles lasting 21 days each, with the possibility of up to 17 cycles over about 12 months. Gemcitabine is given first intravenously over 60 minutes on days 1 and 8 at a fixed dose. Tegavivint is then administered intravenously over 4 hours on days 1, 8, and 15 at dose levels that increase through the study. Treatment stops if the disease progresses or side effects require discontinuation. During the study, participants will undergo regular assessments to monitor disease control, progression-free survival, and overall survival, with the primary measure being the maximum tolerated dose within the first 21 days. Researchers will also evaluate side effects and treatment tolerability. The study lasts up to about three years, with continuous monitoring to assess the treatments effects and safety throughout this period.
CONDITIONS
Brief Title
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Research Team
K
Kate Glasscox, BSN, RN
M
Melissa Schink
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here